HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

C J Bol Selected Research

laniquidar (R101933)

5/2002Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.
4/2000The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


C J Bol Research Topics

Disease

4Neoplasms (Cancer)
06/2002 - 02/2000
1Carcinoma (Carcinomatosis)
06/2002
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2002
1Sleepiness
05/2002
1Mucositis
04/2000
1Fever (Fevers)
04/2000
1Cough
02/2000
1Colonic Neoplasms (Colon Cancer)
02/2000

Drug/Important Bio-Agent (IBA)

4tipifarnib (R115777)IBA
06/2002 - 02/2000
3TransferasesIBA
06/2002 - 02/2000
2Carcinoembryonic AntigenIBA
06/2002 - 02/2000
2Proteins (Proteins, Gene)FDA Link
06/2002 - 02/2000
2laniquidar (R101933)IBA
05/2002 - 04/2000
1Codon (Codons)IBA
06/2002
1Tumor Biomarkers (Tumor Markers)IBA
06/2002
1PlatinumIBA
06/2002
1TabletsIBA
01/2002
1Antineoplastic Agents (Antineoplastics)IBA
01/2002
1Capsules (Microcapsules)IBA
01/2002
1Docetaxel (Taxotere)FDA Link
04/2000

Therapy/Procedure

1Oral Administration
06/2002
1Therapeutics
03/2001